openPR Logo
Press release

Amyotrophic Lateral Sclerosis (ALS) Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | AbbVie, Alector, Amylyx, Annexon, Apellis, Cellenkos, Covis, Cytokinetics, Kadimastem, Prileni

11-29-2023 07:39 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Amyotrophic Lateral Sclerosis (ALS) Pipeline Analysis (2023)

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 90+ key pharma and biotech companies are working on 100+ pipeline drugs in the Amyotrophic Lateral Sclerosis therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Amyotrophic Lateral Sclerosis (ALS) Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Amyotrophic Lateral Sclerosis Therapeutics Market.

The report provides a detailed description of the Amyotrophic Lateral Sclerosis drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Amyotrophic Lateral Sclerosis Clinical Trial Activities and Regulatory Developments in the domain @
https://www.delveinsight.com/report-store/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Amyotrophic Lateral Sclerosis (ALS) Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Amyotrophic Lateral Sclerosis therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Amyotrophic Lateral Sclerosis treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Amyotrophic Lateral Sclerosis drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Amyotrophic Lateral Sclerosis treatment market.

Learn More about the Clinical and Commercial Development Activities in the Amyotrophic Lateral Sclerosis Therapeutics Domain @
https://www.delveinsight.com/report-store/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Amyotrophic Lateral Sclerosis (ALS) Therapeutics Analysis
Currently, there is no cure for ALS and no effective treatment to halt, or reverse, the progression of the disease. The treatment landscape of ALS includes multidisciplinary care, such as physical therapy, speech therapy, dietary counselling, heat or whirlpool therapy and others. Moreover, there are five drugs approved by the US FDA to treat ALS, namely RELYVRIO, Riluzole, NUEDEXTA, RADICAVA (IV and oral), and TIGLUTIK. Medications are also prescribed to help manage symptoms of ALS, including pain, muscle cramps, stiffness, excess saliva and phlegm, and the pseudobulbar affect (involuntary or uncontrollable episodes of crying and/or laughing, or other emotional displays). Drugs are also available to help individuals with pain, depression, sleep disturbances, and constipation.

In September 2022, the FDA approved RELYVRIO (sodium phenylbutyrate and taurursodiol) for treating adults with ALS. RELYVRIO (previously known as AMX0035 in the US). In May 2022, the oral formulation RADICAVA ORS (edaravone) was approved by the US FDA for treating ALS.

To further improve the treatment scenario, several major pharma and biotech companies are developing therapies for Amyotrophic Lateral Sclerosis. Currently, Biogen is leading the therapeutics market with its Amyotrophic Lateral Sclerosis drug candidates in the most advanced stage of clinical development.

Amyotrophic Lateral Sclerosis (ALS) Companies in the Therapeutics Market Include:
AB Science, AbbVie, AI Therapeutics, Inc., AL-S Pharma, Alector Inc., Amylyx Pharmaceuticals, Annexon, Inc., Apellis Pharmaceuticals, Inc., Aquestive Therapeutics, Ashvattha Therapeutics, Inc., Avanir Pharmaceuticals (a subsidiary of Otsuka America), Biogen, Biohaven Pharmaceuticals, Brainstorm Cell Therapeutics, Calico Life Sciences LLC, Cellenkos, Clene Nanomedicine Biosciences, Corcept Therapeutics, Covis, Cytokinetics, Cytokinetics/Astellas Pharma, Denali Therapeutics Inc., DS Pharma, Eledon Pharmaceuticals, Ferrer Internacional S.A., Genuv Inc., Helixmith Co., Ltd., InFlectis BioScience, Ionis Pharmaceuticals, Kadimastem, Knopp Biosciences, MediciNova, Mitsubishi Tanabe Pharma Corporation, Molecular Partners, NeuroSense Therapeutics Ltd., Novartis Pharmaceuticals, Prilenia Therapeutics, Procypra Therapeutics, PTC Therapeutics, QurAlis Corporation, Ra Pharmaceuticals, Rapa Therapeutics LLC, Retrotope, Inc., Revalesio Corporation, Sanofi, PTC Therapeutics, Seelos Therapeutics, UCB Pharma, Woolsey Pharmaceuticals, ZZ Biotech, LLC, and many others.

Emerging and Marketed Amyotrophic Lateral Sclerosis Therapies Covered in the Report Include:
• AMX0035: Amylyx Pharmaceuticals
• ANX005: Annexon
• Exservan: Aquestive Therapeutics
• ION363: Ionis Pharmaceuticals
• Mastitis (AB Sciences
• Nuedexta: Avanir Pharmaceuticals
• Radicava: Mitsubishi Tanabe Pharma Corporation
• RNS60: Revalesio Corporation
• Tiglutik/ Teglutik: ITF Pharma
• Tofersen: Biogen/Ionis Pharmaceuticals
• Verdiperstat: Biohaven
And Many More

Get an in-depth Assessment of the Emerging Therapies and Amyotrophic Lateral Sclerosis Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Amyotrophic Lateral Sclerosis Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates

Route of Administration
Amyotrophic Lateral Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type
Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule

Request for Sample PDF to Understand More About the Amyotrophic Lateral Sclerosis Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Amyotrophic Lateral Sclerosis Current Treatment Patterns
4. Amyotrophic Lateral Sclerosis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Amyotrophic Lateral Sclerosis Late-Stage Products (Phase-III)
7. Amyotrophic Lateral Sclerosis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Amyotrophic Lateral Sclerosis Discontinued Products
13. Amyotrophic Lateral Sclerosis Product Profiles
14. Amyotrophic Lateral Sclerosis Companies
15. Amyotrophic Lateral Sclerosis Drugs
16. Dormant and Discontinued Products
17. Amyotrophic Lateral Sclerosis Unmet Needs
18. Amyotrophic Lateral Sclerosis Future Perspectives
19. Amyotrophic Lateral Sclerosis Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

------------------------------------------------------------------------------------------------------------------------------
Discover DelveInsight's Comprehensive Market Research and Consulting Services:
https://www.delveinsight.com/market-research

Elevate your industry insights with our comprehensive medical devices market assessment reports. Visit to gain a strategic edge through expert analysis and in-depth coverage of the latest trends, innovations, and market dynamics, at:
https://www.delveinsight.com/medical-devices

Empowering Cancer Care: DelveInsight's oncology consulting services offer personalized guidance and cutting-edge expertise to navigate the ongoing clinical, commercial, and regulatory developments, visit for more details:
https://www.delveinsight.com/oncology

Other Trending Healthcare Reports by DelveInsight
Aneurysmal Subarachnoid Hemorrhage (SAH) Market
https://www.delveinsight.com/report-store/aneurysmal-subarachnoid-hemorrhage-sah-market

Dupuytren's Disease Market
https://www.delveinsight.com/report-store/dupuytrens-disease-market

Homocystinuria Market
https://www.delveinsight.com/report-store/homocystinuria-market-new

Platinum-Resistant Relapsed Ovarian Cancer Market
https://www.delveinsight.com/report-store/platinum-resistant-relapsed-ovarian-cancer-market

Dementia with Diabetes Market
https://www.delveinsight.com/report-store/dementia-with-diabetes-market-forecast

Pyruvate Kinase Deficiency Market
https://www.delveinsight.com/report-store/pyruvate-kinase-deficiency-market

Uterine Serous Carcinoma Market
https://www.delveinsight.com/report-store/uterine-serous-carcinoma-market

Paraganglioma Market
https://www.delveinsight.com/report-store/paraganglioma-market

Spinal Cord Stimulators (SCS) Global Market
https://www.delveinsight.com/report-store/spinal-cord-stimulator-market

Adult Spinal Deformity Market
https://www.delveinsight.com/report-store/adult-spinal-deformity-market

Age-related Vision Dysfunction Market
https://www.delveinsight.com/report-store/age-related-vision-dysfunction-market

Erythropoietic Protoporphyria Market
https://www.delveinsight.com/report-store/erythropoietic-protoporphyria-market

Juvenile Idiopathic arthritis (JIA) Market
https://www.delveinsight.com/report-store/juvenile-idiopathic-arthritis-jia-market

Otoscope Market
https://www.delveinsight.com/report-store/otoscope-market

Surgical Energy Generators Market
https://www.delveinsight.com/report-store/surgical-energy-generators-market

Eosinophilic Esophagitis Market
https://www.delveinsight.com/report-store/eosinophilic-esophagitis-market

Hypereosinophilic Syndrome Market
https://www.delveinsight.com/report-store/hypereosinophilic-syndrome-market

Campylobacter Infections Market
https://www.delveinsight.com/report-store/campylobacter-infections-market

Degenerative Disc Disease Market
https://www.delveinsight.com/report-store/degenerative-disc-disease-ddd-market

Optic Neuritis Market
https://www.delveinsight.com/report-store/optic-neuritis-market

Shoulder Replacement Devices Global Market
https://www.delveinsight.com/report-store/shoulder-replacement-devices-market

Scleritis Market
https://www.delveinsight.com/report-store/scleritis-market

Polypoidal Choroidal Vasculopathy (PCV) Market
https://www.delveinsight.com/report-store/polypoidal-choroidal-vasculopathy-market

Post-Polycythemia Vera Myelofibrosis Market
https://www.delveinsight.com/report-store/post-polycythemia-vera-myelofibrosis-market

Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection Market
https://www.delveinsight.com/report-store/severe-acute-respiratory-syndrome-sars-coronavirus-infection-market

Cardiac Biomarkers Testing Devices Global Market
https://www.delveinsight.com/report-store/cardiac-biomarkers-testing-devices-market

Graves Orbitopathy Market
https://www.delveinsight.com/report-store/graves-orbitopathy-market

Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market
https://www.delveinsight.com/report-store/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market

Febrile Neutropenia Market
https://www.delveinsight.com/report-store/febrile-neutropenia-market

Axial Spondyloarthritis Market
https://www.delveinsight.com/report-store/axial-spondyloarthritis-market

Conductive Hearing Loss Market
https://www.delveinsight.com/report-store/conductive-hearing-loss-market

Metastatic Cutaneous Squamous Cell Carcinoma Market
https://www.delveinsight.com/report-store/metastatic-cutaneous-squamous-cell-carcinoma-market

Ocular Melanoma Market
https://www.delveinsight.com/report-store/ocular-melanoma-market

Schistosomiasis Market
https://www.delveinsight.com/report-store/schistosomiasis-market

Adenosine Deaminase-Severe Combined Immunodeficiency Market
https://www.delveinsight.com/report-store/adenosine-deaminase-severe-combined-immunodeficiency-market

Dermal Erythema Market
https://www.delveinsight.com/report-store/dermal-erythema-market

Hypercalcemia Market
https://www.delveinsight.com/report-store/hypercalcemia-market

Marginal Zone Lymphoma Market
https://www.delveinsight.com/report-store/marginal-zone-lymphoma-market

Tonsillitis Market
https://www.delveinsight.com/report-store/tonsillitis-marke

Biliary Atresia Market
https://www.delveinsight.com/report-store/biliary-atresia-market

Endometrial Cancer Market
https://www.delveinsight.com/report-store/endometrial-cancer-market

Retinoblastoma Market
https://www.delveinsight.com/report-store/retinoblastoma-market

Dysautonomia (Autonomic Dysfunction) Market
https://www.delveinsight.com/report-store/dysautonomia-autonomic-dysfunction-market

IgA Nephropathy (IgAN) Market
https://www.delveinsight.com/report-store/iga-nephropathy-market

Kyphoscoliosis Market
https://www.delveinsight.com/report-store/kyphoscoliosis-market

Myofascial Pain Syndrome Market
https://www.delveinsight.com/report-store/myofascial-pain-syndrome-market

Osteogenesis Imperfecta Market
https://www.delveinsight.com/report-store/osteogenesis-imperfecta-oi-market

Treatment-Resistant Depression (TRD) Market
https://www.delveinsight.com/report-store/treatment-resistant-depression-trd-market

Fallopian Tube Cancer Market
https://www.delveinsight.com/report-store/fallopian-tube-cancer-market

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Amyotrophic Lateral Sclerosis (ALS) Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | AbbVie, Alector, Amylyx, Annexon, Apellis, Cellenkos, Covis, Cytokinetics, Kadimastem, Prileni here

News-ID: 3309403 • Views:

More Releases from DelveInsight Business Research LLP

Sapablursen Market Size and Share Across 7MM and Competitive Landscape by DelveInsight | Key Players - Ionis Pharmaceuticals
Sapablursen Market Size and Share Across 7MM and Competitive Landscape by DelveI …
DelveInsight has released a comprehensive report titled "Sapablursen Market Forecast" offering a thorough examination and predictive insights into the Sapablursen market landscape until 2032 across the seven major markets (7MM), encompassing the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The extensive report offers a thorough examination of the market potential and market share of Sapablursen in the therapeutics landscape for Polycythemia Vera across the 7MM,
Sapablursen Market Size and Share Analysis Across 7MM and Competitive Landscape by DelveInsight | Key Players - Ionis Pharmaceuticals
Sapablursen Market Size and Share Analysis Across 7MM and Competitive Landscape …
DelveInsight has released a comprehensive report titled "Sapablursen Market Forecast" offering a thorough examination and predictive insights into the Sapablursen market landscape until 2032 across the seven major markets (7MM), encompassing the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The extensive report offers a thorough examination of the market potential and market share of Sapablursen in the therapeutics landscape for Polycythemia Vera across the 7MM,
Complicated Urinary Tract Infections (cUTIs) Market Poised for Extraordinary Growth During the Forecast Period (2023-32), Asserts DelveInsight | Allecra Therapeutics (EXBLIFEP (cefepime/enmetazobactam)), Iterum, Venatorx, Nabriva, Wockhardt, MerLion
Complicated Urinary Tract Infections (cUTIs) Market Poised for Extraordinary Gro …
The Complicated Urinary Tract Infections (cUTIs) market is dynamically evolving with the development of novel antimicrobial agents, increased focus on antibiotic stewardship, and advancements in diagnostic technologies, offering the potential for more targeted and effective treatment options. Growing awareness of antibiotic resistance and the demand for alternative therapies are driving innovation and shaping the landscape of cUTI management, fostering improved patient outcomes. DelveInsight's "Complicated Urinary Tract Infections (cUTIs) Market Insights, Epidemiology,
Multiple Sclerosis Market Forecasts by DelveInsight Signal Groundbreaking Growth by 2032 | TG Therapeutics (BRIUMVI/ ublituximab-xiiy), Immunic, ANOKION, Osmotica Pharma, Alkermes, Biogen, Merck Healthcare, Clene Nanomedicine, Atara Biotherapeutics
Multiple Sclerosis Market Forecasts by DelveInsight Signal Groundbreaking Growth …
The Multiple Sclerosis (MS) market is experiencing significant evolution with the introduction of innovative disease-modifying therapies, advancements in precision medicine approaches, and increasing emphasis on personalized treatment strategies, promising improved management and outcomes for patients. Ongoing research efforts and the expanding understanding of the underlying mechanisms of Multiple Sclerosis are driving innovation and shaping the landscape, ushering in a new era of care for individuals affected by this complex neurological

All 5 Releases


More Releases for Amyotrophic

Global Amyotrophic Lateral Sclerosis Devices Market $19.5 Billion by 2029
The global market for amyotrophic lateral sclerosis devices or motor neuron disease devices anticipated to reach $19.5 billion by 2029, growing at a CAGR of 7.3% over the forecast period, driven by increasing incidence, rising geriatric population, lack of curative treatment, growing public awareness, and technological advancements in palliative care. https://www.ihealthcareanalyst.com/global-amyotrophic-lateral-sclerosis-devices-market/ Amyotrophic lateral sclerosis or Lou Gehrig's disease or motor neuron disease (MND) is characterized by progressive degeneration of the motor nerve
Amyotrophic Lateral Sclerosis Treatment Market Report Up to 2031
Visiongain has published a new report on Amyotrophic Lateral Sclerosis Treatment Market Report to 2031: Forecasts by Treatment Type (Chemotherapy and Stem Cell Therapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) PLUS COVID-19 Recovery Scenarios. Download Exclusive Sample of Report @ https://www.visiongain.com/report/als-treatment-market/#download_sampe_div COVID-19 Impact on Amyotrophic Lateral Sclerosis Treatment Market The COVID-19 pandemic has deleteriously affected all the countries and industries. Similarly, the Amyotrophic Lateral Sclerosis Treatment market is anticipated
Amyotrophic Lateral Sclerosis Treatment Market Growth and Opportunity Analysis
Allied Market Research published a report, titled, “Amyotrophic Lateral Sclerosis Treatment Market: Global Opportunity Analysis and Industry Forecast 2019–2026.” According to the report, the global Amyotrophic Lateral Sclerosis Treatment industry garnered $XX billion in 2019, and is expected to generate $xx billion by 2027, witnessing a CAGR of xx% from 2020 to 2027. Click Here To Access Sample Report https://www.alliedmarketresearch.com/request-sample/10609 Major players analyzed include Sun Pharmaceutical, Mitsubishi Tanabe Pharma America, Biogen,
Global Amyotrophic Lateral Sclerosis Market Research Report - Forecast to 2023
Amyotrophic Lateral Sclerosis Market 2020 comprises a detailed survey of the Amyotrophic Lateral Sclerosis Market size, share, trends, extension, consumption, and share, segments, application and Forecast 2025. Global "Amyotrophic Lateral Sclerosis" Market 2020-2025 Report contains all demographic as well as analytical data regarding market review, growth, demand, and budget analysis. The report mainly highlights the significant trends of the Amyotrophic Lateral Sclerosis market in terms of thriving companies, business methods, product
Amyotrophic Lateral Sclerosis (ALS) Treatment Market : Trends And Growth
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease and motor neuron disease (MND), is a neurodegenerative disease, affecting nerve cells in the brain and spinal cord that controls voluntary muscles. The disease is progressive in nature, meaning it gets worse over time. According to a study published in Centers for Disease Control and Prevention, in 2016, around 14,713 people were diagnosed with ALS in the U.S. and prevalence rate
Amyotrophic Lateral Sclerosis Market to increase rapidly by 2024
Amyotrophic lateral sclerosis (ALS) is a neurological disease and also termed as Lou Gehrig’s disease.  The disease affects the motor neurons, which control the action of voluntary muscles, as a result the messages between brain and muscle fibers are blocked. ALS could occur in a person due to genetic inheritance, mutation in gene which encodes enzyme copper-zinc superoxide dismutase coupled with defect in chromosome 9. This disease is more prevalent